Table 1 Baseline characteristics of main CvLPRIT trial and immediate versus staged in-hospital complete revascularisation CMR substudy participants
Variable | CvLPRIT cohort (n = 296) | Immediate CR (n = 63) | Staged CR (n = 30) | p |
|---|---|---|---|---|
Age (y) | 64.9 ± 11.6 | 63.0 ± 11.6 | 65.0 ± 10.3 | 0.42 |
Male sex (%) | 240/296 (81.1) | 55 (87.3) | 28 (93.3) | 0.38 |
BMI (kg/m2) | 27.3 (24.4–30.2) | 27.7 ± 4.5 | 27.6 ± 4.1 | 0.95 |
Heart rate (beats per minute) | 74.4 ± 17.6 | 71.9 ± 16.4 | 73.5 ± 18.0 | 0.68 |
Systolic BP (mmHg) | 137.6 ± 27.1 | 132.6 ± 26.8 | 140.0 ± 27.7 | 0.23 |
Anterior infarct (%) | 106 (35.6) | 21 (33.3) | 11 (36.7) | 0.75 |
eGFR (ml/min/1.73) | 95.74 ± 34.7 | 96.1 ± 30.2 | 101.5 ± 41.0 | 0.49 |
Hypertension (%) | 105/287 (36.6) | 24 (38.1) | 10 (33.3) | 0.66 |
Hypercholesterolemia (%) | 75/287 (26.1) | 16 (25.4) | 12 (40.0) | 0.15 |
Diabetes Mellitus (%) | 39/287 (13.6) | 11 (17.5) | 4 (13.3) | 0.61 |
Current smoker (%) | 87/285 (30.5) | 23 (36.5) | 10 (33.3) | 0.77 |
Previous MI (%) | 12/287 (4.2) | 4 (6.3) | 0 (0.0) | 0.16 |
Previous PCI (%) | 9/287 (3.1) | 4 (6.3) | 0 (0.0) | 0.16 |
Anti-anginal medication (B/N) | 54/287 (18.8) | 8/63 (12.7) | 5/29 (17.2) | 0.56 |
Killip Class II-III (%) | 24/286 (8.4) | 4 (6.3) | 2 (6.7) | 0.95 |